170 related articles for article (PubMed ID: 32905653)
1. Circulating CD14
Stenzel AE; Abrams SI; Joseph JM; Goode EL; Tario JD; Wallace PK; Kaur D; Adamson AK; Buas MF; Lugade AA; Laslavic A; Taylor SE; Orr B; Edwards RP; Elishaev E; Odunsi K; Mongiovi JM; Etter JL; Winham SJ; Kaufmann SH; Modugno F; Moysich KB
Am J Reprod Immunol; 2021 Mar; 85(3):e13343. PubMed ID: 32905653
[TBL] [Abstract][Full Text] [Related]
2. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
3. Elevated frequencies of CD14
Xue G; Jiang M; Zhao R; Le A; Li J
Aging (Albany NY); 2021 Feb; 13(5):6236-6246. PubMed ID: 33640878
[TBL] [Abstract][Full Text] [Related]
4. The CD14
Mengos AE; Gastineau DA; Gustafson MP
Front Immunol; 2019; 10():1147. PubMed ID: 31191529
[TBL] [Abstract][Full Text] [Related]
5. [The expression and association of CD14(+) HLA-DR(Low/-) myeloid-derived suppressor cell-like cells and interleukin-1β in ovarian cancer].
Wang HY; Zhao R; Ren H; Zou MJ; Zhang J; Zhang Y
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2663-2669. PubMed ID: 28910953
[No Abstract] [Full Text] [Related]
6. CD14
Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment.
Väyrynen JP; Haruki K; Väyrynen SA; Lau MC; Dias Costa A; Borowsky J; Zhao M; Ugai T; Kishikawa J; Akimoto N; Zhong R; Shi S; Chang TW; Fujiyoshi K; Arima K; Twombly TS; Da Silva A; Song M; Wu K; Zhang X; Chan AT; Nishihara R; Fuchs CS; Meyerhardt JA; Giannakis M; Ogino S; Nowak JA
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931472
[TBL] [Abstract][Full Text] [Related]
8. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
9. Circulating immunosuppressive cells of prostate cancer patients before and after radical prostatectomy: profile comparison.
Brusa D; Simone M; Gontero P; Spadi R; Racca P; Micari J; Degiuli M; Carletto S; Tizzani A; Matera L
Int J Urol; 2013 Oct; 20(10):971-8. PubMed ID: 23421558
[TBL] [Abstract][Full Text] [Related]
10. Increased Levels of Circulating Monocytic- and Early-Stage Myeloid-Derived Suppressor Cells (MDSC) in Acute Myeloid Leukemia.
Lv J; Zhao Y; Zong H; Ma G; Wei X; Zhao Y
Clin Lab; 2021 Mar; 67(3):. PubMed ID: 33739029
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients.
Li J; Srivastava RM; Ettyreddy A; Ferris RL
J Immunother Cancer; 2015; 3():54. PubMed ID: 26579227
[TBL] [Abstract][Full Text] [Related]
12. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
[TBL] [Abstract][Full Text] [Related]
13. Healthy myeloid-derived suppressor cells express the surface ectoenzyme Vanin-2 (VNN2).
Soler DC; Kerstetter-Fogle A; Young AB; Rayman P; Finke JH; Debanne SM; Cooper KD; Barnholtz-Sloan J; Sloan AE; McCormick TS
Mol Immunol; 2022 Feb; 142():1-10. PubMed ID: 34953280
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
15. CD14, CD16 and HLA-DR reliably identifies human monocytes and their subsets in the context of pathologically reduced HLA-DR expression by CD14(hi) /CD16(neg) monocytes: Expansion of CD14(hi) /CD16(pos) and contraction of CD14(lo) /CD16(pos) monocytes in acute liver failure.
Abeles RD; McPhail MJ; Sowter D; Antoniades CG; Vergis N; Vijay GK; Xystrakis E; Khamri W; Shawcross DL; Ma Y; Wendon JA; Vergani D
Cytometry A; 2012 Oct; 81(10):823-34. PubMed ID: 22837127
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.
Vuk-Pavlović S; Bulur PA; Lin Y; Qin R; Szumlanski CL; Zhao X; Dietz AB
Prostate; 2010 Mar; 70(4):443-55. PubMed ID: 19902470
[TBL] [Abstract][Full Text] [Related]
17. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus.
Chen MF; Kuan FC; Yen TC; Lu MS; Lin PY; Chung YH; Chen WC; Lee KD
Oncotarget; 2014 Sep; 5(18):8716-28. PubMed ID: 25238263
[TBL] [Abstract][Full Text] [Related]
18. The study of CD14+HLA-DR-/low myeloid-drived suppressor cell (MDSC) in peripheral blood of peripheral T-cell lymphoma patients and its biological function.
Du J; Sun X; Song Y
Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):62-67. PubMed ID: 28466815
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo/neg Monocytes Correlate with Decreased Survival in Patients with Clear Cell Renal Cell Carcinoma.
Gustafson MP; Lin Y; Bleeker JS; Warad D; Tollefson MK; Crispen PL; Bulur PA; Harrington SM; Laborde RR; Gastineau DA; Leibovich BC; Cheville JC; Kwon ED; Dietz AB
Clin Cancer Res; 2015 Sep; 21(18):4224-33. PubMed ID: 25999436
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
